Back to News
Market Impact: 0.4
Definium's DT120 ODT Achieves Significant Anxiety Improvement In Phase 3 Trial; Stock Up
Source: Nasdaq
Healthcare & Biotech
Definium Therapeutics announced positive topline results from Panorama, its second Phase 3 trial of DT120 (lysergide) orally disintegrating tablets for adults with generalized anxiety disorder. The successful late-stage study advances the drug candidate's clinical-development and potential regulatory pathway, representing a material positive catalyst for DFTX.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
DFTX0.82
More News
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- This hospice services stock is outperforming the S&P 500. Jefferies sees more gains ahead
- Waters’ new AI tool targets one of the pharmaceutical industry’s most tedious tasks
- Biotechs buck a sluggish IPO market, but investors should tread warily
- Wedbush cuts Geron stock price target to $5 on study halt
- Needham initiates Clover Health stock with buy on cohort economics